Research coauthored by RTI Health Solutions experts will be presented at ASCO 2024.
Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: a SEER-Medicare analysis. Brufsky A, Sandin R, Stergiopoulos S, Chen C, Karanth SD, Li B, Esterberg L, Makari D, Candrilli S, Goyal RK, Rugo HS. Poster
Session Type and Title:
Poster Session – Breast Cancer—Metastatic
Session Date and Time:
6/2/2024
9:00 AM-12:00 PM CDT
Poster Board # 89.
